Clinical Trials Details

Central Nervous System Metastatis

DTI_002, Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC_PEN) in malignancies involving the Central Nervous System

Objective

This phase II study is for patients with metastatic disease involving the Central Nervous System (CNS) who no other standard treatment options are available. The focus is on melanoma, breast, lung and primary CNS cancers.

IRB Protocol Number

DTI-022

Principal Investigator(s)

Roger Santala, MD

Contact

Susan Dillon, RN BSN OCN at 406-435-7443
or sdillon1@billingsclinic.org